TABLE 2.
Antibiotic (μg/piece)a | Inhibition halo (cm) |
|||
---|---|---|---|---|
B6-2 | B6-2ΔsrpABC | B6-2ΔttgABC | B6-2ΔsrpSΔttgABC | |
Ampicillin (10) | Nob | No | 1.9 ± 0.1 | No |
Cefepime (30) | 2.6 ± 0.2 | 2.6 ± 0.2 | 3.6 ± 0.1 | 3.0 ± 0.2 |
Cefotaxime (30) | 1.9 ± 0.1 | 1.8 ± 0.1 | 3.4 ± 0.1 | 2.5 ± 0.1 |
Cefoxitin (30) | No | No | 2.8 ± 0.2 | No |
Ceftazidime (30) | 2.5 ± 0.0 | 2.3 ± 0.2 | 2.9 ± 0.2 | 2.7 ± 0.1 |
Nalidixic acid (30) | 1.8 ± 0.3 | 1.8 ± 0.2 | 3.1 ± 0.2 | 2.4 ± 0.1 |
Novobiocin (30) | No | No | 1.5 ± 0.0 | 0.8 ± 0.1 |
Tetracycline (30) | 1.3 ± 0.3 | 1.3 ± 0.1 | 2.3 ± 0.1 | 1.9 ± 0.0 |
Chloramphenicol (30) | No | No | 1.1 ± 0.1 | 0.9 ± 0.1 |
Erythromycin (15) | No | No | 1.5 ± 0.1 | 2.0 ± 0.0 |
Gentamicin (10) | 1.5 ± 0.1 | 1.6 ± 0.0 | 2.2 ± 0.1 | 2.3 ± 0.1 |
Meropenem (10) | 0.8 ± 0.1 | 1.0 ± 0.2 | 2.5 ± 0.2 | 2.6 ± 0.2 |
Spectinomycin (100) | No | No | 1.5 ± 0.2 | 2.5 ± 0.1 |
Streptomycin (10) | No | No | 2.0 ± 0.1 | 2.1 ± 0.0 |
Fourteen of the 20 antibiotics tested in this assay are shown. There were no differences found in susceptibility to rifampin, fosfomycin, teicoplanin, nystatin, lincomycin, or polymyxin B.
No, no bacteriostatic ring.